There are 2789 resources available
1388P - Efficacy of second line immunotherapy in advanced upper gastrointestinal tract malignancies: A pooled analysis of randomized clinical trials
Presenter: Panagiotis Ntellas
Session: ePoster Display
1320TiP - The efficacy and safety of stereotactic body radiation therapy (SBRT) plus toripalimab with or without bevacizumab as second-line treatment for advanced non-small cell lung cancer (NSCLC): A prospective, multicenter, open-label, phase II study
Presenter: Jianguo Sun
Session: ePoster Display
1321P - Real-world treatments and clinical outcomes in advanced NSCLC without actionable mutations after introduction of immunotherapy (IO) in Japan
Presenter: Hiroshi Nokihara
Session: ePoster Display
1322P - Development and external validation of a novel four-gene-pair signature for predicting clinical response to anti-PD-1 immunotherapy of non-small cell lung cancer
Presenter: Chengming Liu
Session: ePoster Display
1323P - Immunotherapy for PDL1-high (TPS≥50%) metastatic NSCLC: Results in real-world oncology practice
Presenter: Drazena Srdic
Session: ePoster Display
1324P - Clinical and laboratory features: How they influence immunotherapy response in non-small cell lung cancer
Presenter: Ricardo Gomes
Session: ePoster Display
1325P - Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315)
Presenter: Frank Griesinger
Session: ePoster Display
1326P - Combination of stereotactic ablative radiotherapy with anti-PD-1 in oligoprogressive disease: Final results of a prospective multicenter study
Presenter: Juan Zafra Martín
Session: ePoster Display
1327P - Impact of bone targeted agents (BTA) in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD(L)1 inhibitors (ICIs)
Presenter: Sara Manglaviti
Session: ePoster Display